Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings.
OBJECTIVE
To report a case of biopsy-documented nonalcoholic steatohepatitis (NASH), which improved appreciably through moderate exercise and weight loss in a young woman with polycystic ovary syndrome (PCOS) and insulin resistance.


METHODS
We present a detailed case report, including laboratory and pathologic findings. In addition, we review the recent literature regarding the association of insulin resistance with NASH and PCOS.


RESULTS
A 24-year-old woman was referred to the Duke Gastroenterology Clinic for evaluation of long-term high serum aminotransferase levels. She also reported a history of chronically irregular menses, infertility, and hirsutism and was diagnosed with PCOS. Subsequent glucose tolerance testing suggested the presence of insulin resistance. Liver biopsy findings were consistent with severe nonalcoholic steatohepatitis. Under the supervision of her physician and an exercise physiologist, the patient initiated a diet and exercise program that resulted in an 11.5% weight loss during approximately 8 months and yielded normalization of her aminotransferase levels. A repeat liver biopsy done 13 months after the initial biopsy revealed a substantial decrease in steatosis and a reduction in inflammation.


CONCLUSIONS
Women with PCOS and insulin resistance have an increased risk of developing many of the consequences of the dysmetabolic syndrome, including type 2 diabetes, hypertension, and hyperlipidemia. This case report suggests that fatty liver and NASH may be other important diseases to identify in such women. It also demonstrates the improvement in this condition with moderate exercise and weight loss.
Brown
Ann J
AJ
Department of Medicine, Division of Endocrinology, Duke, University Medical Center, Durham, North Carolina 27710, USA.
Tendler
David A
DA
McMurray
Robert G
RG
Setji
Tracy L
TL
D000328:Adult; D001706:Biopsy; D015444:Exercise; D005234:Fatty Liver / Q000150:complications* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005260:Female; D006505:Hepatitis / Q000150:complications / Q000628:therapy; D006801:Humans; D007328:Insulin / Q000502:physiology; D007333:Insulin Resistance; D008099:Liver / Q000473:pathology*; D024821:Metabolic Syndrome / Q000097:blood / Q000473:pathology / Q000503:physiopathology; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D012307:Risk Factors; D013739:Testosterone / Q000097:blood; D000637:Transaminases / Q000097:blood; D015431:Weight Loss
D007328:Insulin; D013739:Testosterone; D000637:Transaminases